For individuals or couples aware of a family history of muscular dystrophy, the prospect of starting a family often comes with significant concerns regarding the inheritance of the condition. Pre-implantation genetic testing (PGT) is a sophisticated medical procedure used alongside In Vitro Fertilisation (IVF) to identify embryos that carry specific genetic mutations. By screening embryos before they are implanted in the womb, this technology allows prospective parents to significantly reduce the risk of passing on muscle-wasting disorders to their children. This guide explains how the process works within the UK healthcare system, the eligibility criteria for patients, and the clinical steps involved in ensuring a healthy pregnancy.
What We’ll Discuss in This Article
- How PGT-M specifically targets the mutations responsible for muscular dystrophy.
- The clinical steps of the IVF and embryo biopsy process.
- Eligibility requirements for NHS-funded genetic testing in the UK.
- A comparison between pre-implantation testing and prenatal screening.
- The emotional and ethical considerations for families undergoing PGT.
- Limitations and success rates of genetic selection technologies.
Understanding PGT-M and Muscular Dystrophy
Pre-implantation genetic testing for monogenic disorders (PGT-M) can effectively help avoid passing on muscular dystrophy by screening embryos created through IVF and only transferring those that do not carry the specific genetic mutation. This specialist procedure is used in the UK to help people with a high risk of passing on a serious inherited condition have a child who is unaffected. This form of testing is highly specific, as it requires the clinical team to know the exact genetic mutation present in the family before the process begins.
Muscular dystrophy refers to a group of genetic conditions that cause progressive muscle weakness and wasting. Because many of these conditions, such as Duchenne muscular dystrophy, follow a predictable pattern of inheritance, scientists can look for the specific gene responsible at the earliest stages of embryonic development. Unlike general screening, PGT-M is a bespoke process where a “test” is created specifically for the couple’s unique genetic makeup.
The Human Fertilisation and Embryology Authority regulates which genetic conditions are eligible for testing in UK fertility clinics. If a specific type of muscular dystrophy is on the approved list, and the couple meets the clinical criteria, they can proceed with a cycle of IVF that includes this genetic screening. This provides an alternative to traditional prenatal testing, which occurs only after a pregnancy has already been established.
The Clinical Process of Embryo Screening
The process of PGT-M begins with a standard cycle of In Vitro Fertilisation to produce multiple embryos for testing. The woman undergoes hormonal stimulation to produce several eggs, which are then collected and fertilised with the partner’s or a donor’s sperm in a laboratory. Once the embryos reach the blastocyst stage, which is usually around five days after fertilisation, a few cells are carefully removed for genetic analysis.
This biopsy is performed by highly skilled embryologists using a precise laser. The removed cells are then sent to a specialist genetics laboratory where the DNA is analysed to see if the muscular dystrophy mutation is present. During this time, the embryos are frozen and stored safely. The analysis can determine which embryos are unaffected, which are carriers (who may pass the gene on but not show symptoms), and which are affected by the condition.
Once the results are available, a single unaffected embryo is chosen for transfer into the woman’s womb. Any remaining unaffected embryos can stay frozen for future use. While the biopsy and freezing processes are advanced, they are generally considered safe for the development of the embryo. However, the complexity of the laboratory work means that not every IVF cycle will result in an unaffected embryo being available for transfer.
Eligibility and NHS Funding in the UK
In the UK, the NHS may provide funding for PGT-M if the couple meets strict national criteria, ensuring that those at the highest risk of passing on severe conditions have access to care. Generally, for a couple to be eligible for NHS-funded PGT-M, they must have a confirmed genetic diagnosis of a serious condition and no living unaffected children. Additionally, the female partner must usually be under the age of 40 and have a healthy Body Mass Index (BMI).
The decision to fund PGT-M is often managed by local Integrated Care Boards (ICBs), and the number of funded cycles can vary. Most eligible couples are offered up to three cycles of treatment. If a couple does not meet the NHS criteria, for example, if they already have one healthy child but want to ensure their next child is also unaffected, they may choose to self-fund the treatment at a licensed private fertility clinic.
Referral for PGT-M usually begins at a regional genetics centre. A genetic counsellor will discuss the inheritance risks and the implications of the testing with the couple. This specialist input is vital for ensuring that the parents fully understand the technical and emotional aspects of the journey before committing to the intensive process of IVF.
Comparison of Genetic Testing Methods
Choosing between pre-implantation testing and testing during pregnancy is a significant decision for many families. The following table compares PGT-M with traditional prenatal testing methods like Chorionic Villus Sampling (CVS) or Amniocentesis.
| Feature | PGT-M (Pre-implantation) | Prenatal Testing (CVS/Amniocentesis) |
| Timing | Before pregnancy begins. | During pregnancy (11 to 16 weeks). |
| Procedure | Requires IVF and embryo biopsy. | Needle biopsy of placenta or fluid. |
| Main Advantage | Avoids the decision of termination. | Natural conception is possible. |
| Main Disadvantage | Lower success rate per cycle. | Risk of miscarriage from the test. |
| NHS Availability | Strict eligibility and limited cycles. | Available to all at high risk. |
| Emotional Impact | Stress of IVF and embryo selection. | Stress of potential termination. |
Ethical and Emotional Support
Undergoing PGT-M is an emotionally demanding journey that requires significant resilience from both partners. The process involves multiple stages of waiting, from the results of egg collection to the final genetic report on the embryos. It is common for couples to feel a sense of grief for the embryos that are found to be affected, as well as anxiety about the success of the IVF transfer.
Counselling is a mandatory part of the PGT-M process in the UK. Fertility clinics provide specialist counsellors who can help couples navigate the ethical complexities of selecting embryos. Some individuals may struggle with the idea of “discarding” affected embryos, while others feel a deep sense of relief at the possibility of breaking a cycle of genetic illness within their family.
It is also important for couples to discuss how much information they wish to receive. For example, in some X-linked conditions like Duchenne muscular dystrophy, the laboratory may be able to determine the sex of the embryo. Some parents prefer not to know this information unless it is clinically necessary for the testing process. Professional support ensures that these decisions are made in a way that respects the couple’s values and emotional well-being.
Limitations and Success Rates
While PGT-M is highly accurate, it is not a 100% guarantee of an unaffected pregnancy. There is a small margin of error in genetic testing, usually around 1% to 2%, which means that a follow-up prenatal test like an amniocentesis may still be recommended by some clinical teams. Furthermore, the success of the procedure is heavily dependent on the success of the underlying IVF cycle.
Success rates for PGT-M are influenced by the age of the woman and the number of healthy eggs produced. Not all collected eggs will fertilise, and not all fertilised eggs will reach the blastocyst stage. If a couple has a 50% risk of passing on a condition, it is statistically possible that none of the embryos created in a single cycle will be unaffected.
Patients must also consider the physical toll of IVF, which includes hormonal injections and a minor surgical procedure for egg retrieval. Despite these challenges, PGT-M remains the most effective way for families with a history of muscular dystrophy to plan for a future without the condition. The technology continues to evolve, with improvements in embryo freezing and genetic sequencing further increasing the reliability of these specialist services.
Conclusion
Pre-implantation genetic testing is a highly effective clinical tool that allows families to avoid passing on muscular dystrophy by selecting unaffected embryos before a pregnancy is established. The process requires a specialist multi-disciplinary team and involves a combination of IVF, embryo biopsy, and advanced genetic analysis. While the journey can be emotionally and physically challenging, the availability of NHS funding and regulated clinical pathways in the UK provides a safe and structured route for eligible couples. Understanding the limitations and the requirements of the process is essential for anyone considering this technology as part of their family planning.
If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is PGT-M the same as making a “designer baby”?
No, PGT-M is a strictly regulated medical procedure used only to avoid serious and life-limiting genetic conditions, not to select for non-medical traits.
What happens to the embryos that have muscular dystrophy?
Embryos that are found to be affected are usually allowed to perish naturally or, with the couple’s consent, may be donated to medical research.
Can I use PGT-M if I already have a child with muscular dystrophy?
While you can use PGT-M, you may not be eligible for NHS funding if you already have a child, meaning you might need to fund the treatment privately.
Does the embryo biopsy hurt the future baby?
Current medical evidence suggests that removing a few cells at the blastocyst stage does not increase the risk of birth defects or developmental issues.
How long does the whole process take?
From the initial genetic consultation to the embryo transfer, the process can take between six months and a year, depending on wait times and laboratory work.
Is PGT-M available for all types of muscular dystrophy?
It is available for most types where the specific gene is known, but the condition must be approved by the HFEA for use in UK clinics.
What is the success rate of PGT-M?
Success rates vary, but they generally mirror standard IVF success rates for the woman’s age group, provided that unaffected embryos are available.
Authority Snapshot (E-E-A-T Block)
This guide was developed by the Medical Content Team and reviewed by Dr. Stefan Petrov, a UK-trained physician with experience in general medicine, surgery, and emergency care. The information provided adheres to NHS clinical standards and HFEA regulations regarding genetic testing and assisted reproduction in the UK. Our goal is to provide accurate, safe, and transparent information to help patients understand the complex options available for genetic family planning.
